Litigations Updates
-
A Los Angeles jury has awarded a total of $40 million in a landmark, month-long bellwether trial involving ovarian cancer claims tied to Johnson & Johnson’s talc products. The verdict was reached after approximately six hours of jury deliberation. The jury concluded that Johnson & Johnson’s talc products were a substantial contributing factor in causing…
-
A Missouri appellate court has upheld a $611 million judgment against Bayer, affirming that its Roundup weedkiller caused cancer in three plaintiffs. This decision maintains the original jury verdict from November 2023, which found Bayer liable for negligence, selling a defective product, and failing to warn consumers about the risks associated with Roundup’s active ingredient,…
-
A Georgia state court awarded John Barnes $2.065 billion after he developed non-Hodgkin lymphoma from using Monsanto’s Roundup. The award includes $65 million in compensatory damages and $2 billion in punitive damages. Barnes claimed Monsanto concealed risks of glyphosate, the weed killer’s active ingredient. Monsanto plans to appeal.
-
Settlement talks with Monsanto may result in a global compensation plan for Roundup claims, but past negotiations show Monsanto could abandon the process. Two major challenges exist: Monsanto’s preemption defense, which the Supreme Court may reconsider, and the threat of bankruptcy, which would weaken claimants’ positions significantly.
-
As of April 2025, the Camp Lejeune litigation sees approximately 2,770 lawsuits filed, with 25 bellwether trials set for late 2025. The claim filing window closed in August 2024, leading to ongoing settlement discussions and new bipartisan legislation aimed at expediting resolutions. Over 546,500 claims have been received by the Navy.
-
On April 1, 2025, a U.S. Bankruptcy Judge rejected J&J’s $9 billion bankruptcy plan aimed at settling over 60,000 talc lawsuits due to flaws in the voting process. J&J will return to civil court for litigation, asserting its products are safe. Meanwhile, over 58,000 lawsuits remain pending, impacting J&J’s stock negatively.